WALTHAM, Mass.–(BUSINESS WIRE)–Mar 21, 2022–
This week on the Drug, Chemical & Associated Technologies Association (DCAT) convention in New York, NY, Thermo Fisher Scientific will spotlight its investments and innovation throughout its world pharma companies community from improvement to industrial.
“We proceed to take a position strategically in each world capability and superior capabilities that simplify the availability chain and speed up the tempo of pharmaceutical improvement,” stated Leon Wyszkowski, president of business operations, pharma companies, Thermo Fisher Scientific. “Our focus has been on growing built-in capabilities that join the whole worth chain — from early improvement and scale-up to industrial manufacturing — in addition to leveraging new transformative digital applied sciences to assist velocity the supply of breakthrough medicines and therapies to sufferers.”
Simplifying the Provide Chain for Cell and Gene Therapies
The demand for cell and gene therapies is fueling exponential progress. This yr, Thermo Fisher will open one of many largest viral vector websites in North America. The practically 300,000-square-foot facility in Plainville, Mass., will lengthen the corporate’s world industrial viral vector community to 6 websites.
Later this yr, Thermo Fisher will develop its cell remedy community with the addition of a new cell remedy improvement and cGMP manufacturing heart on the College of California San Francisco, Mission Bay campus. The location will present prospects with built-in options to cut back price and speed up adoption of cell therapies.
To handle the necessity for commercial-quality plasmid DNA, Thermo Fisher opened its new cGMP Plasmid manufacturing facility in Carlsbad, Calif., to help scientific and industrial wants for top of the range uncooked materials and drug substance improvement for cell and gene therapies and vaccines.
Moreover, the corporate can be launching new mRNA synthesis capabilities to provide drug substance for vaccines and therapies
Enabling Early-Stage Course of Growth
Thermo Fisher has added new capabilities to help early-stage improvement, shorten pre-clinical examine timelines and speed up commercialization. New translational sciences labs will open in San Diego, Calif., and Alachua, Fla., to help cell and gene remedy improvement for the pharmaceutical innovators transitioning drug candidates into pre-clinical research.
As well as, new Fast to Clinic built-in companies join companies throughout the worth chain and create workflows to permit fast course of improvement and lowered cycle occasions. New Fast to Take care of superior therapies presents an end-to-end, customizable resolution that integrates drug improvement and scientific companies throughout the cell and gene remedy worth chain to hurry entry to breakthrough therapies. New Patheon Business Packaging Companies for Cell and Gene Therapies mix GMP storage, serialization, ultracold and cryogenic packaging, and world distribution to satisfy specialised wants to make sure CGT provide chain integrity.
Increasing Steriles, Product Growth & Biologics Capabilities
The corporate has expanded its capabilities to help the accelerated demand for world steriles and biologics manufacturing. Over the past two years, Thermo Fisher has added 13 new aseptic filling traces and expanded its product improvement companies throughout its world community.
Thermo Fisher is doubling biologics manufacturing capability at its St. Louis, Mo., web site to help manufacturing progress from 2KL to 5KL. As well as, the corporate assumed operational accountability of its new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, which options extremely versatile bioproduction applied sciences and offers a pathway from improvement to large-scale manufacturing.
Later this yr, the corporate will develop into Asia-Pacific. In Hangzhou, China, a brand new manufacturing facility would be the first to supply built-in biologics drug substance and sterile drug product capabilities. In Singapore, a brand new sterile manufacturing facility will provide large-scale capability and high-speed filling.
Digital Transformation of the Provide Chain
Thermo Fisher is leveraging new digital applied sciences throughout its pharma companies community to create manufacturing efficiencies and streamlined processes. New capabilities embody implementation of Pharma 4.0 to harmonize and combine knowledge and drive digital transformation inside all phases of drug improvement and manufacturing. As well as, the corporate’s new mysupply digital provide chain platform offers prospects with visibility and collaboration throughout their full product lifecycle together with each day order administration, batch monitoring and month-to-month forecasting.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world chief in serving science, with annual income of roughly $40 billion. Our Mission is to allow our prospects to make the world more healthy, cleaner and safer. Whether or not our prospects are accelerating life sciences analysis, fixing complicated analytical challenges, growing productiveness of their laboratories, bettering affected person well being via diagnostics or the event and manufacture of life-changing therapies, we’re right here to help them. Our world group delivers an unequalled mixture of revolutionary applied sciences, buying comfort and pharmaceutical companies via our industry-leading manufacturers, together with Thermo Scientific, Utilized Biosystems, Invitrogen, Fisher Scientific, Unity Lab Companies, Patheon and PPD. For extra info, please go to www.thermofisher.com.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20220321005824/en/
Thermo Fisher Scientific
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK MASSACHUSETTS
INDUSTRY KEYWORD: RESEARCH MEDICAL SUPPLIES INFECTIOUS DISEASES GENETICS CLINICAL TRIALS BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE
SOURCE: Thermo Fisher
Copyright Enterprise Wire 2022.
PUB: 03/21/2022 04:05 PM/DISC: 03/21/2022 04:06 PM